Bull, base and bear scenarios, opening on what this business has actually done — its realised growth rates and its own P/E range, not round numbers we chose.
Projections are part of Pro
Set the growth, margin and multiple yourself and watch the price land where your assumptions put it — for Amgen Inc. and every other company we cover.
Try it first on NVDA, AAPL, META, NKE or CAKE, where it is open to everyone.
$465.73-0.3%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 4, 2026
Amgen discovers, makes and sells prescription medicines for serious diseases, along with biosimilar medicines.
Company outlook: revenue of $38.9B to $39.7B for Fiscal year 2026 — up 6.9% on a year earlier